

"For the same reasons that *Sony* took the staple-article doctrine of patent law as a model for its copyright safe-harbor rule, the inducement rule, too, is a sensible one for copyright. We adopt it here, holding that one who distributes a device with the object of promoting its use to infringe copyright, as shown by clear expression or other affirmative steps taken to foster infringement, is liable for the resulting acts of infringement by third parties. We are, of course, mindful of the need to keep from trenching on regular commerce or discouraging the development of technologies with lawful and unlawful potential. Accordingly, just as *Sony* did not find intentional inducement despite the knowledge of the VCR manufacturer that its device could be used to infringe, mere knowledge of infringing potential or of actual infringing uses would not be enough here to subject a distributor to liability. Nor would ordinary acts incident to product distribution, such as offering customers technical support or product updates, support liability in themselves. The inducement rule, instead, premises liability on purposeful, culpable expression and conduct, and thus does nothing to compromise legitimate commerce or discourage innovation having a lawful promise."

2. Property in One's Person

Remember the foundation of Locke's labor theory of property, stated on page 14: "every man has a property in his own person." Slavery, obviously, was in opposition to that proposition (and so, it appears, were some of Locke's activities), but slavery has been abolished. So, can we now say, without qualification, that you have property in yourself? Consider the following case.

Moore v. Regents of the University of California

Supreme Court of California, 1990
793 P.2d 479
cert. denied, 499 U.S. 936 (1991)

[*Background:* In 1976 John Moore sought treatment for hairy-cell leukemia at the Medical Center of the University of California, Los Angeles. (We shall at times refer to the doctors at the Center and to the Regents of the University who own the Center collectively as "defendants.") The defendants conducted tests, took blood and tissue samples, confirmed the diagnosis, and told Moore that his condition was life-threatening and that his spleen should be removed. What they did not tell Moore was that his cells were unique and that access to them was of great scientific and commercial value.

Moore consented to the splenectomy and to some seven years of follow-up tests and procedures that he was led to believe were important to his treatment. His spleen was retained for research purposes without his knowledge or consent, and during the post-operative period samples of tissue and blood and other fluids were taken on each of Moore's visits. At some point Moore was informed that his bodily substances were being used for research, but he was never informed of the com-

mercial value of the research or of the defendants' financial interest in it. The defendants subsequently established a cell line from Moore's cells (named the Mo cell line, after Moore), received a patent for it, and entered into various commercial agreements. Hundreds of thousands of dollars had been paid to the defendants under these agreements by the mid-1980s, and the potential market for products from Moore's cell line is estimated to run into the billions of dollars.


Moore sued for damages in 1984, his complaint stating a number of causes of action, including conversion (wrongful exercise of ownership rights over the personal property of another; Moore alleged that his blood and bodily substances, and the cell line derived from them, were "his tangible personal property"), lack of informed consent, breach of fiduciary duty, fraud and deceit, unjust enrichment, intentional infliction of emotional distress, negligent misrepresentation, and others. The trial court sustained the defendants' demurrers to the conversion cause of action and held that because the conversion cause of action was incorporated into all the other causes of action, those too were defective.

The court of appeal reversed, finding that Moore had adequately stated a cause of action for conversion. *Moore v. Regents of the University of California*, 249 Cal. Rptr. 494 (Ct. App. 1988). The court could find "no legal authority, public policy, nor universally known facts of biological science... which compel a conclusion that this plaintiff cannot have a sufficient legal interest in his own bodily tissues amounting to personal property. Absent plaintiff's consent to defendants' disposition of the tissues, or lawful justification, such as abandonment, the complaint adequately pleads all the elements of a cause of action for conversion."

"We have approached this issue with caution," the court said. "The evolution of civilization from slavery to freedom, from regarding people as chattels to recognition of the individual dignity of each person, necessitates prudence in attributing the qualities of property to human tissue. There is, however, a dramatic difference between having property rights in one's own body and being the property of another.... We are not called on to determine whether use of human tissue or body parts ought to be 'gift based' or subject to a 'free market.' That question of policy must be determined by the Legislature. In the instant case, the cell line has already been commercialized by defendants. We are presented a *fait accompli*, leaving only the question of who shares in the proceeds...."

The court then considered the meaning of property and concluded that the essential element is dominion, or rights of use, control, and disposition. It went on to discuss the "many cases" (involving search and seizure, consent to medical procedures, rights to dead bodies, and other instances) that recognize "rights of dominion over one's own body, and the interests one has therein.... These rights and interests are so akin to property interests that it would be a subterfuge to call them something else."

The court concluded by dealing with a series of contentions by defendants. There were no grounds to infer that Moore had abandoned his tissue or consented to its use in research unrelated to his treatment. And the fact that the defendants' skill and effort had enhanced the value of Moore's tissue went not to the issue of conversion but to the measure of damages for the conversion. "Plaintiff's cells and genes are a part of his person," the court said, citing the right of publicity cases that "afford legal protection to an individual's proprietary interest in his own identity." To hold that patients do not have the ultimate power to control the destiny of



United States Patent

Goldie et al.

[1] 4,438,032

[2] Mar. 20, 1984

UNIQUE T-LYMPHOCYTE LINE AND PRODUCTS DERIVED THEREFROM

[3] Inventors: David W. Goldie; Shirley G. Qian;

both of Los Angeles, Calif.

[4] Assignee: The Regents of the University of

California, Berkeley, Calif.

[5] Appl. No. 486,177

[6] Filed Jan. 6, 1983

[7] Related U.S. Application Data

Continuation of Ser. No. 275,000, Jan. 30, 1981, aban-

doned

[8] Int. Cl.¹ C12P 21/00; C12N 15/00

[9] U.S. Cl. 260/132 R; 260/112 R

[10] 424/95; 424/177; 435/94; 435/172; 435/240;

435/241; 435/948

[11] Field of Search 260/112 R; 112 R;

435/94; 172; 240; 241; 948

[12] References Cited

U.S. PATENT DOCUMENTS

4,318,397 7/1982 Gilbert 435/94

OTHER PUBLICATIONS

Saeton et al., *Annals of Internal Medicine*, (1978),

58:321-326.

Weidart et al., *Clin. Immunology & Immunopathol-*

ogy, (1975), 14:441-448.

Freidart et al., *J. Lab. Clin. Med.*, (1979), 93:622-626.

Goldie et al., *In Vivo and In Vitro Erythropoiesis*, 1980,

pp. 97-106.

Goldie et al., *Blood*, (1978), 51:1068-1071.

Goldie et al., *PNAS, USA*, (1980), 77:593-596.

Goldie et al., *Annals of Internal Medicine*, (1980),

92:650-662.

Primary Examiner—Howard E. Schun

Attorney, Agent or Firm—Berriman E. Rowland

ABSTRACT

Human T-lymphoblast cell line, Prostemocytin produces

produced thymocytes, messenger RNA, and a T-lym-

phoblast cell line (Mo) maintained at a continuous cul-

tured constitutively produces proteins, including tumor

interferon, neutrophil migration inhibiting factor,

granulocyte-macrophage colony-stimulating activity

and erythropoietin activity, as well as other

proteins produced by T-cells.

22 Claims, No Drawings

Pages from the Mo Cell Line Patent

their tissues "would open the door to a massive invasion of human privacy and dignity in the name of medical progress." The court saw no reason to believe that medical research would suffer by requiring the consent of the donor of tissue before it can be appropriated. True, a potential donor, once informed, might refuse consent, but the court "would give the patient that right. As to defendants' concern that a patient might seek the greatest economic gain for his participation, this argument is unpersuasive because it fails to explain why defendants... are any more to be trusted with these momentous decisions than the person whose cells are being used." If giving patients a financial interest in their tissues inhibited donations and increased the costs of medical care, that problem could be addressed by the legislature.

Upon petition by the defendants, the court of appeal's judgment was reviewed by the California Supreme Court. Of particular interest here are the views of the various justices regarding the cause of action for conversion.]

PANELLI, J. granted review in this case to determine whether plaintiff has stated a cause of action against his physician and other defendants for using his cells in potentially lucrative medical research without his permission.... We hold that the complaint states a cause of action for breach of the physician's disclosure obligations, but not for conversion....

A. Breach of Fiduciary Duty and Lack of Informed Consent

Moore repeatedly alleges that Golde [the attending physician] failed to disclose the extent of his research and economic interests in Moore's cells before obtaining consent to the medical procedures by which the cells were extracted. These allegations, in our view, state a cause of action against Golde for invading a legally protected interest of his patient. This cause of action can properly be characterized either as the breach of a fiduciary duty to disclose facts material to the patient's consent or, alternatively, as the performance of medical procedures without first having obtained the patient's informed consent....

B. Conversion

Moore also attempts to characterize the invasion of his rights as a conversion—a tort that protects against interference with possessory and ownership interests in personal property. He theorizes that he continued to own his cells following their removal from his body, at least for the purpose of directing their use, and that he never consented to their use in potentially lucrative medical research. Thus, to complete Moore's argument, defendants' unauthorized use of his cells constitutes a conversion. As a result of the alleged conversion, Moore claims a proprietary interest in each of the products that any of the defendants might ever create from his cells or the patented cell line.

No court, however, has ever in a reported decision imposed conversion liability for the use of human cells in medical research. While that fact does not end our inquiry, it raises a flag of caution. In effect, what Moore is asking us to do is to impose a tort duty on scientists to investigate the consensual pedigree of each human cell sample used in research. To impose such a duty, which would affect

medical rese
removed fro
conversion a
loser or the
results of s
micals that

We hav
theory of lia
important t

Accord
Moore a ca
of the novel
theory of c
extension o
extend the

1. M

"To es
his ownersh
alleged to
action for

Sinc
their rem
interest in
such inter
directly or
continuing
Regents' p
be Moore

Neith
discloses
support a
laws go
fetuses, p
gical mat
goals rat
these spe
should ar

Lack
Moore re
rights. O
(1979) 2

35. Se
permits a
"transplan
science."
"valuable

medical research of importance to all of society, implicates policy concerns far removed from the traditional, two-party ownership disputes in which the law of conversion arose. Invoking a tort theory originally used to determine whether the loser or the finder of a horse had the better title, Moore claims ownership of the results of socially important medical research, including the genetic code for chemicals that regulate the functions of every human being's immune system.

We have recognized that, when the proposed application of a very general theory of liability in a new context raises important policy concerns, it is especially important to face those concerns and address them openly....

Accordingly, we first consider whether the tort of conversion clearly gives Moore a cause of action under existing law. We do not believe it does. Because of the novelty of Moore's claim to own the biological materials at issue, to apply the theory of conversion in this context would frankly have to be recognized as an extension of the theory. Therefore, we consider next whether it is advisable to extend the tort to this context.

1. Moore's Claim Under Existing Law

"To establish a conversion, plaintiff must establish an actual interference with his *ownership or right of possession*. . . . Where plaintiff neither has title to the property alleged to have been converted, nor possession thereof, he cannot maintain an action for conversion." . . .

Since Moore clearly did not expect to retain possession of his cells following their removal, to sue for their conversion he must have retained an ownership interest in them. But there are several reasons to doubt that he did retain any such interest. First, no reported judicial decision supports Moore's claim, either directly or by close analogy. Second, California statutory law drastically limits any continuing interest of a patient in excised cells. Third, the subject matters of the Regents' patent—the patented cell line and the products derived from it—cannot be Moore's property.

Neither the Court of Appeal's opinion, the parties' briefs, nor our research discloses a case holding that a person retains a sufficient interest in excised cells to support a cause of action for conversion. We do not find this surprising, since the laws governing such things as human tissues, transplantable organs,³⁵ blood, fetuses, pituitary glands, corneal tissue, and dead bodies deal with human biological materials as objects *sui generis*, regulating their disposition to achieve policy goals rather than abandoning them to the general law of personal property. It is these specialized statutes, not the law of conversion, to which courts ordinarily should and do look for guidance on the disposition of human biological materials.

Lacking direct authority for importing the law of conversion into this context, Moore relies, as did the Court of Appeal, primarily on decisions addressing privacy rights. One line of cases involves unwanted publicity. (*Lugosi v. Universal Pictures* (1979) 25 Cal. 3d 813, 160 Cal. Rptr. 323, 603 P.2d 425; *Motsehenbacher v. R.J.*

35. See the Uniform Anatomical Gift Act, Health and Safety Code sections 7150 et seq. The act permits a competent adult to "give all or part of [his] body" for certain designated purposes, including "transplantation, therapy, medical or dental education, research, or advancement of medical or dental science." (Health & Saf. Code, §§7151, 7153.) The act does not, however, permit the donor to receive "valuable consideration" for the transfer. (Health & Saf. Code, §7155.)

Reynolds Tobacco Company (9th Cir. 1974) 498 F.2d 821.) These opinions hold that every person has a proprietary interest in his own likeness and that unauthorized, business use of a likeness is redressible as a tort. But in neither opinion did the authoring court expressly base its holding on property law. Each court stated, following Prosser, that it was "pointless" to debate the proper characterization of the proprietary interest in a likeness. For purposes of determining whether the tort of conversion lies, however, the characterization of the right in question is far from pointless. Only property can be converted.

Not only are the wrongful-publicity cases irrelevant to the issue of conversion, but the analogy to them seriously misconceives the nature of the genetic materials and research involved in this case. Moore, adopting the analogy originally advanced by the Court of Appeal, argues that "[i]f the courts have found a sufficient proprietary interest in one's persona, how could one not have a right in one's own genetic material, something far more profoundly the essence of one's human uniqueness than a name or a face?" However, as the defendants' patent makes clear—and the complaint, too, if read with an understanding of the scientific terms which it has borrowed from the patent—the goal and result of defendants' efforts has been to manufacture lymphokines. Lymphokines, unlike a name or a face, have the same molecular structure in every human being and the same important functions in every human being's immune system. Moreover, the particular genetic material which is responsible for the natural production of lymphokines, and which defendants use to manufacture lymphokines in the laboratory, is also the same in every person; it is no more unique to Moore than the number of vertebrae in the spine or the chemical formula of hemoglobin.

... [T]he Court of Appeal in this case concluded that "[a] patient must have the ultimate power to control what becomes of his or her tissues. To hold otherwise would open the door to a massive invasion of human privacy and dignity in the name of medical progress." Yet one may earnestly wish to protect privacy and dignity without accepting the extremely problematic conclusion that interference with those interests amounts to a conversion of personal property. Nor is it necessary to force the round pegs of "privacy" and "dignity" into the square hole of "property" in order to protect the patient, since the fiduciary-duty and informed-consent theories protect these interests directly by requiring full disclosure.

The next consideration that makes Moore's claim of ownership problematic is California statutory law, which drastically limits a patient's control over excised cells. Pursuant to Health and Safety Code section 7054.4, "[n]otwithstanding any other provision of law, recognizable anatomical parts, human tissues, anatomical human remains, or infectious waste following conclusion of scientific use shall be disposed of by interment, incineration, or any other method determined by the state department [of health services] to protect the public health and safety." Clearly the Legislature did not specifically intend this statute to resolve the question of whether a patient is entitled to compensation for the nonconsensual use of excised cells. A primary object of the statute is to ensure the safe handling of potentially hazardous biological waste materials. Yet one cannot escape the conclusion that the statute's practical effect is to limit, drastically, a patient's control over excised cells. By restricting how excised cells may be used and requiring their eventual destruction, the statute eliminates so many of the rights ordinarily

attached to property that one cannot simply assume that what is left amounts to "property" or "ownership" for purposes of conversion law.

... A fully informed patient may always withhold consent to treatment by a physician whose research plans the patient does not approve. That right, however, as already discussed, is protected by the fiduciary-duty and informed-consent theories.

Finally, the subject matter of the Regents' patent — the patented cell line and the products derived from it — cannot be Moore's property. This is because the patented cell line is both factually and legally distinct from the cells taken from Moore's body. Federal law permits the patenting of organisms that represent the product of "human ingenuity," but not naturally occurring organisms. . . . It is this *inventive effort* that patent law rewards, not the discovery of naturally occurring raw materials. Thus, Moore's allegations that he owns the cell line and the products derived from it are inconsistent with the patent, which constitutes an authoritative determination that the cell line is the product of invention. . . .

2. Should Conversion Liability Be Extended?

... There are three reasons why it is inappropriate to impose liability for conversion based upon the allegations of Moore's complaint. First, a fair balancing of the relevant policy considerations counsels against extending the tort. Second, problems in this area are better suited to legislative resolution. Third, the tort of conversion is not necessary to protect patients' rights. For these reasons, we conclude that the use of excised human cells in medical research does not amount to a conversion.

Of the relevant policy considerations, two are of overriding importance. The first is protection of a competent patient's right to make autonomous medical decisions. That right, as already discussed, is grounded in well-recognized and long-standing principles of fiduciary duty and informed consent. . . . This policy weighs in favor of providing a remedy to patients when physicians act with undisclosed motives that may affect their professional judgment. The second important policy consideration is that we not threaten with disabling civil liability innocent parties who are engaged in socially useful activities, such as researchers who have no reason to believe that their use of a particular cell sample is, or may be, against a donor's wishes.

To reach an appropriate balance of these policy considerations is extremely important. In its report to Congress the Office of Technology Assessment emphasized that

[u]ncertainty about how courts will resolve disputes between specimen sources and specimen users could be detrimental to both academic researchers and the infant biotechnology industry, particularly when the rights are asserted long after the specimen was obtained. The assertion of rights by sources would affect not only the researcher who obtained the original specimen, but perhaps other researchers as well.

Biological materials are routinely distributed to other researchers for experimental purposes, and scientists who obtain cell lines or other specimen-derived products, such as gene clones, from the original researcher could also be sued under certain legal theories

[such as conversion]. Furthermore, the uncertainty could affect product developments as well as research. Since inventions containing human tissues and cells may be patented and licensed for commercial use, companies are unlikely to invest heavily in developing, manufacturing, or marketing a product when uncertainty about clear title exists. . . .

Indeed, so significant is the potential obstacle to research stemming from uncertainty about legal title to biological materials that the Office of Technology Assessment reached this striking conclusion: "[R]egardless of the merit of claims by the different interested parties, resolving the current uncertainty may be more important to the future of biotechnology than resolving it in any particular way." . . .

We need not, however, make an arbitrary choice between liability and non-liability. Instead, an examination of the relevant policy considerations suggests an appropriate balance: Liability based upon existing disclosure obligations, rather than an unprecedented extension of the conversion theory, protects patients' rights of privacy and autonomy without unnecessarily hindering research.

To be sure, the threat of liability for conversion might help to enforce patients' rights indirectly. This is because physicians might be able to avoid liability by obtaining patients' consent, in the broadest possible terms, to any conceivable subsequent research use of excised cells. Unfortunately, to extend the conversion theory would utterly sacrifice the other goal of protecting innocent parties. Since conversion is a strict liability tort, it would impose liability on all those into whose hands the cells come, whether or not the particular defendant participated in, or knew of, the inadequate disclosures that violated the patient's right to make an informed decision. In contrast to the conversion theory, the fiduciary-duty and informed-consent theories protect the patient directly, without punishing innocent parties or creating disincentives to the conduct of socially beneficial research.

Research on human cells plays a critical role in medical research. This is so because researchers are increasingly able to isolate naturally occurring, medically useful biological substances and to produce useful quantities of such substances through genetic engineering. These efforts are beginning to bear fruit. Products developed through biotechnology that have already been approved for marketing in this country include treatments and tests for leukemia, cancer, diabetes, dwarfism, hepatitis-B, kidney transplant rejection, emphysema, osteoporosis, ulcers, anemia, infertility, and gynecological tumors, to name but a few. . . .

The extension of conversion law into this area will hinder research by restricting access to the necessary raw materials. Thousands of human cell lines already exist in tissue repositories. . . . At present, human cell lines are routinely copied and distributed to other researchers for experimental purposes, usually free of charge. This exchange of scientific materials, which still is relatively free and efficient, will surely be compromised if each cell sample becomes the potential subject matter of a lawsuit.

To expand liability by extending conversion law into this area would have a broad impact. The House Committee on Science and Technology of the United States Congress found that "49 percent of the researchers at medical institutions surveyed used human tissues or cells in their research." . . . In addition, "there are nearly 350 commercial biotechnology firms in the United States actively engaged in biotechnology research and commercial product development and approximately 25 to 30 percent appear to be engaged in research to develop a human

therapeutic or diagnostic reagent. . . . Most, but not all, of the human therapeutic products are derived from human tissues and cells, or human cell lines or cloned genes." . . .

In deciding whether to create new tort duties we have in the past considered the impact that expanded liability would have on activities that are important to society, such as research. . . .

[T]he theory of liability that Moore urges us to endorse threatens to destroy the economic incentive to conduct important medical research. If the use of cells in research is a conversion, then with every cell sample a researcher purchases a ticket in a litigation lottery. Because liability for conversion is predicated on a continuing ownership interest, "companies are unlikely to invest heavily in developing, manufacturing, or marketing a product when uncertainty about clear title exists." . . .

If the scientific users of human cells are to be held liable for failing to investigate the consensual pedigree of their raw materials, we believe the Legislature should make that decision. . . .

[T]here is no pressing need to impose a judicially created rule of strict liability, since enforcement of physicians' disclosure obligations will protect patients against the very type of harm with which Moore was threatened. So long as a physician discloses research and economic interests that may affect his judgment, the patient is protected from conflicts of interest. Aware of any conflicts, the patient can make an informed decision to consent to treatment, or to withhold consent and look elsewhere for medical assistance. As already discussed, enforcement of physicians' disclosure obligations protects patients directly, without hindering the socially useful activities of innocent researchers.

For these reasons, we hold that the allegations of Moore's third amended complaint state a cause of action for breach of fiduciary duty or lack of informed consent, but not conversion. . . .

Lucas, C.J., Eagleson, J., and Kennard, J., concurred.

ARABIAN, J., concurring. I join in the views cogently expounded by the majority. I write separately to give voice to a concern that I believe informs much of that opinion but finds little or no expression therein. I speak of the moral issue.

Plaintiff has asked us to recognize and enforce a right to sell one's own body tissue *for profit*. He entreats us to regard the human vessel—the single most venerated and protected subject in any civilized society—as equal with the basest commercial commodity. He urges us to commingle the sacred with the profane. He asks much. . . .

It is true, that this court has not often been deterred from deciding difficult legal issues simply because they require a choice between competing social or economic policies. . . . The difference here, however, lies in the nature of the conflicting moral, philosophical and even religious values at stake, and in the profound implications of the position urged. The ramifications of recognizing and enforcing a property interest in body tissues are not known, but are greatly feared—the effect on human dignity of a marketplace in human body parts, the impact on research and development of competitive bidding for such materials, and the exposure of researchers to potentially limitless and uncharted tort liability. . . .

Whether, as plaintiff urges, his cells should be treated as property susceptible to conversion is not, in my view, ours to decide.

Where then shall a complete resolution be found? Clearly the Legislature, as the majority opinion suggests, is the proper deliberative forum. Indeed, a legislative response creating a licensing scheme, which establishes a fixed rate of profit sharing between researcher and subject, has already been suggested. Such an arrangement would not only avoid the moral and philosophical objections to a free market operation in body tissue, but would also address stated concerns by eliminating the inherently coercive effect of a waiver system and by compensating donors regardless of temporal circumstances.

[The concurring and dissenting opinion of Justice Broussard is omitted.]

MOSK, J. I dissent. Contrary to the principal holding of the Court of Appeal, the majority conclude that the complaint does not—in fact cannot—state a cause of action for conversion. I disagree with this conclusion for all the reasons stated by the Court of Appeal, and for additional reasons.

The concepts of property and ownership in our law are extremely broad.

Being broad, the concept of property is also abstract: rather than referring directly to a material object such as a parcel of land or the tractor that cultivates it, the concept of property is often said to refer to a "bundle of rights" that may be exercised with respect to that object—principally the rights to possess the property, to use the property, to exclude others from the property, and to dispose of the property by sale or by gift. But the same bundle of rights does not attach to all forms of property. For a variety of policy reasons, the law limits or even forbids the exercise of certain rights over certain forms of property. For example, both law and contract may limit the right of an owner of real property to use his parcel as he sees fit. Owners of various forms of personal property may likewise be subject to restrictions on the time, place, and manner of their use. Limitations on the disposition of real property, while less common, may also be imposed. Finally, some types of personal property may be sold but not given away,³⁶ while others may be given away but not sold,³⁷ and still others may neither be given away nor sold.³⁸

In each of the foregoing instances, the limitation or prohibition diminishes the bundle of rights that would otherwise attach to the property, yet what remains is still deemed in law to be a protectible property interest. . . . The same rule applies to Moore's interest in his own body tissue. . . . Above all, at the time of its excision he at least had the right to do with his own tissue whatever the defendants did with it: i.e., he could have contracted with researchers and pharmaceutical companies to develop and exploit the vast commercial potential of his tissue and its products.

Having concluded—mistakenly, in my view—that Moore has no cause of action for conversion under existing law, the majority next consider whether to

36. A person contemplating bankruptcy may sell his property at its "reasonably equivalent value," but he may not make a gift of the same property. (See 11 U.S.C. §548(a).)

37. A sportsman may give away wild fish or game that he has caught or killed pursuant to his license, but he may not sell it. (Fish & G. Code, §§3039, 7121.)

The transfer of human organs and blood is a special case discussed below.

38. E.g., a license to practice a profession, or a prescription drug in the hands of the person for whom it is prescribed.

"extend" the conversion cause of action to this context. Again... I respectfully disagree with [their reasoning].

...[O]ur society acknowledges a profound ethical imperative to respect the human body as the physical and temporal expression of the unique human persona. One manifestation of that respect is our prohibition against direct abuse of the body by torture or other forms of cruel or unusual punishment. Another is our prohibition against indirect abuse of the body by its economic exploitation for the sole benefit of another person. The most abhorrent form of such exploitation, of course, was the institution of slavery. Lesser forms, such as indentured servitude or even debtor's prison, have also disappeared. Yet their specter haunts the laboratories and boardrooms of today's biotechnological research-industrial complex. It arises wherever scientists or industrialists claim, as defendants claim here, the right to appropriate and exploit a patient's tissue for their sole economic benefit—the right, in other words, to freely mine or harvest valuable physical properties of the patient's body....

A second policy consideration adds notions of equity to those of ethics. Our society values fundamental fairness in dealings between its members, and condemns the unjust enrichment of any member at the expense of another. This is particularly true when, as here, the parties are not in equal bargaining positions.... Yet defendants deny that Moore is entitled to any share whatever in the proceeds of this cell line. This is both inequitable and immoral....

There will be... equitable sharing if the courts recognize that the patient has a legally protected property interest in his own body and its products: "property rights in one's own tissue would provide a morally acceptable result by giving effect to notions of fairness and preventing unjust enrichment...."

I do not doubt that the Legislature is competent to act on this topic. The fact that the Legislature may intervene if and when it chooses, however, does not in the meanwhile relieve the courts of their duty of enforcing—or if need be, fashioning—an effective judicial remedy for the wrong here alleged....

The inference I draw from the current statutory regulation of human biological materials, moreover, is the opposite of that drawn by the majority. By selective quotation of the statutes [see page 73, footnote 35] the majority seem to suggest that human organs and blood cannot legally be sold on the open market—thereby implying that if the Legislature were to act here it would impose a similar ban on monetary compensation for the use of human tissue in biotechnological research and development. But if that is the argument, the premise is unsound: contrary to popular misconception, it is not true that human organs and blood cannot legally be sold.

As to organs, the majority rely on the Uniform Anatomical Gift Act (Health & Saf. Code, §7150 et seq., hereafter the UAGA) for the proposition that a competent adult may make a post mortem gift of any part of his body but may not receive "valuable consideration" for the transfer. But the prohibition of the UAGA against the sale of a body part is much more limited than the majority recognize: by its terms (Health & Saf. Code, §7155, subd. (a)) the prohibition applies only to sales for "transplantation" or "therapy." Yet a different section of the UAGA authorizes the transfer and receipt of body parts for such additional purposes as "medical or dental education, research, or advancement of medical or dental science." (Health & Saf. Code, §7153, subd. (a)(1).) No section of the UAGA prohibits anyone from

selling body parts for any of those additional purposes; by clear implication, therefore, such sales are legal.³⁹ Indeed, the fact that the UAGA prohibits *no* sales of organs other than sales for "transplantation" or "therapy" raises a further implication that it is also legal for anyone to sell human tissue to a biotechnology company for research and development purposes....

It follows that the statutes regulating the transfers of human organs and blood do not support the majority's refusal to recognize a conversion cause of action for commercial exploitation of human blood cells without consent. On the contrary, because such statutes treat both organs and blood as property that can legally be sold in a variety of circumstances, they impliedly support Moore's contention that his blood cells are likewise property for which he can and should receive compensation, and hence are protected by the law of conversion.

The majority's final reason for refusing to recognize a conversion cause of action on these facts is that "there is no pressing need" to do so because the complaint also states another cause of action that is assertedly adequate to the task....

I disagree, however, with the majority's further conclusion that in the present context a nondisclosure cause of action is an adequate — in fact, a superior — substitute for a conversion cause of action....

The majority do not spell out how those obligations will be "enforced"; but because they arise from judicial decision (the majority opinion herein) rather than from legislative or administrative enactment, we may infer that the obligations will primarily be enforced by the traditional judicial remedy of an action for damages for their breach....

The remedy is largely illusory. "[A]n action based on the physician's failure to disclose material information sounds in negligence. As a practical matter, however, it may be difficult to recover on this kind of negligence theory because the patient must prove a *causal connection* between his or her injury and the physician's failure to inform." (Martin & Lagod, *Biotechnology and the Commercial Use of Human Cells: Toward an Organic View of Life and Technology* (1989), 5 Santa Clara Computer & High Tech L.J. 211, 222, fn. omitted, italics added.) There are two barriers to recovery. First, "the patient must show that if he or she had been informed of all pertinent information, he or she would have declined to consent to the procedure in question." (Ibid.)...

The second barrier to recovery is still higher, and is erected on the first: it is not even enough for the plaintiff to prove that he personally would have refused consent to the proposed treatment if he had been fully informed; he must also prove that in the same circumstances *no reasonably prudent person* would have given such consent....

The second reason why the nondisclosure cause of action is inadequate for the task that the majority assign to it is that it fails to solve half the problem before us: it gives the patient only the right to *refuse* consent, i.e., the right to prohibit the

39. "By their terms... the statutes in question forbid only sales for transplantation and therapy. In light of the rather clear authorization for donation for research and education, one could conclude that sales for these non-therapeutic purposes are permitted. Scientists in practice have been buying and selling human tissues for research apparently without interference from these statutes." (Note, "She's Got Bette Davis[s] Eyes": Assessing the Nonconsensual Removal of Cadaver Organs Under the Takings and Due Process Clauses, 90 Colum. L. Rev. 528, 544, fn.75 (1990).)

commercialization of his tissue; it does not give him the right to *grant* consent to that commercialization on the condition that he share in its proceeds. . . .

Reversing the words of the old song, the nondisclosure cause of action thus accentuates the negative and eliminates the positive: the patient can say no, but he cannot say yes and expect to share in the proceeds of his contribution. . . .

Third, the nondisclosure cause of action fails to reach a major class of potential defendants: all those who are outside the strict physician-patient relationship with the plaintiff. Thus the majority concede that here only defendant Golde, the treating physician, can be directly liable to Moore on a nondisclosure cause of action. . . .

In sum, the nondisclosure cause of action (1) is unlikely to be successful in most cases, (2) fails to protect patients' rights to share in the proceeds of the commercial exploitation of their tissue, and (3) may allow the true exploiters to escape liability. It is thus not an adequate substitute, in my view, for the conversion cause of action. . . .

NOTES AND QUESTIONS: PROPERTY IN ONE'S PERSON

1. *More to Moore than meets the eye.* The excerpts from *Moore* reproduced above are only a fraction (but the essential fraction) of the opinions in the case, which consume in their entirety 65 pages of the official reporter. (The pages of law review and other commentary run many times that number.)

There's more to *Moore* in another, more substantial sense, as Justice Arabian makes plain when he addresses in his concurring opinion (see pages 77-78) "a concern that . . . informs much of [the majority] opinion but finds little or no expression therein." The concern in question is actually twofold: recognition of property rights in one's cells would (a) necessarily entail "a right to sell one's own body tissue for profit" and (b) thereby give rise to the grave difficulties Arabian suggests.

2. *A bundle of rights.* But (a) is incorrect, as one can gather from the first few paragraphs of Justice Mosk's dissenting opinion (see pages 78-81). For lawyers, if not lay people, property is an abstraction. It refers not to things, material or otherwise, but to rights or relationships among people with respect to things. And the abstraction we call property is multi- not monolithic. It consists of a number of disparate rights, a "bundle" of them: the right to possess, the right to use, the right to exclude, the right to transfer.⁴⁰

Regarding the last, note that while property may usually be transferred by sale or by gift, this is not always the case. As Justice Mosk explains, sometimes gifts alone are permitted, sometimes only sales, sometimes neither. Notwithstanding, we are still talking about property.⁴¹

40. In recent years the bundle-of-rights conception has come under attack. See, e.g., Joseph William Singer, *Entitlement: The Paradoxes of Property* 9-13 (2000); Hanoch Dagan, *The Craft of Property*, 91 *Calif. L. Rev.* 1517 (2003); Adam Mossoff, *What is Property? Putting the Pieces Back Together*, 45 *Ariz. L. Rev.* 371 (2003); Craig Anthony Arnold, *The Reconstitution of Property: Property as a Web of Interests*, 26 *Harv. Envtl. L. Rev.* 281 (2002); J.E. Penner, *The "Bundles of Rights" Picture of Property*, 43 *UCLA L. Rev.* 711 (1996); J.L. Schroeder, *Chix Nix Bundle-O-Stix: A Feminist Critique of the Disaggregation of Property*, 93 *Mich. L. Rev.* 239 (1994).

41. When sales are prohibited but gifts allowed, property is sometimes said to be "market-inalienable." When the situation is reversed, one might say that the property is *only* market-alienable. When neither mode of transfer is permitted, the property is inalienable. Justice Mosk gives examples of each in footnotes 36-38. Can you think of others? See generally Susan Rose-Ackerman, *Inalienability and the*